Tag: Mayo Clinic

Help for Medicare Advantage Patients Who Lose Doctors Is Shelved, for Now

RETIRING        Nationwide, hospitals and other providers are leaving private Medicare Advantage plans, putting thousands of seniors at risk of higher costs and of losing trusted doctors.

Amy Trojanowski liked the extra benefits her Humana Medicare Advantage plan provided — a $200 debit card replenished monthly to use toward groceries, over-the-counter pharmacy items and even her electric bill. She also appreciated the dental and vision coverage. But those things couldn’t compare to the doctor she had been seeing for nearly a decade.

“I love her so much,” said Ms. Trojanowski, 60, who lives near Raleigh, N.C. The doctor’s practice is part of UNC Health, a 20-hospital system affiliated with the University of North Carolina at Chapel Hill.

Last October, however, Humana informed her that UNC Health would no longer participate in the plan’s provider network in 2026….

In November, the Centers for Medicare & Medicaid Services proposed a regulation with a solution for Advantage members “who experience provider network changes midyear” and “may want to stay with their current provider,” according to a C.M.S. fact sheet. Officials would streamline a complicated process “to allow these enrollees to change their coverage more easily.” State insurance officials, the American Medical Association and the American Hospital Association, along with other provider and patient advocacy groups, generally supported the idea.

But early this month, C.M.S. abandoned the proposal, which would have taken effect in 2027, even as disruptions in provider networks continue. C.M.S. officials declined to explain the reason for the reversal. But in an email, a C.M.S. spokesman, Christopher Krepich, wrote that the agency “routinely proposes policies to solicit public input and carefully considers all feedback” before finalizing them. [Continued in The New York Times.]

Legal challenges threaten Biden’s COVID-19 vaccine rule

Volume 398, Issue 10314
20 November 2021

 

WORLD REPORT  Almost a year after the first COVID-19 vaccine was approved for emergency use in the USA, roughly a third of adults have still not received it. After urging Americans to get vaccinated, US President Joe Biden has taken a tougher approach: under his administration’s new workplace safety standard, people must get vaccinated or undergo weekly tests for the virus if they work for companies with at least 100 employees. “The rule will protect more than 84 million workers from the spread of the coronavirus on the job”, said Jim Frederick, Deputy Assistant Secretary of Labor for Occupational Safety and Health. …A day after OSHA’s announcement on Nov 4, 2021, multiple lawsuits to block the rule started rolling in to federal courts across the country.[Continued here.]  

 …

US FDA defends approval of Alzheimer’s disease drug

Volume 398, Issue 10294
3 July 2021

 

WORLD REPORT An avalanche of criticism has forced the US Food and Drug Administration to defend its decision to grant accelerated approval for aducanumab, the first new Alzheimer’s disease treatment in two decades. “It will be a very long time before we ever figure out whether or not this drug really works”, said Aaron Kesselheim, professor of medicine at Brigham and Women’s Hospital and Harvard Medical School who resigned in protest from an FDA advisory panel that recommended against approval.[Continued here.]

 …

Federal Regulators split on antimalarials for COVID-19

Volume 395    Number 10231     
11 April 2020                          
WORLD REPORT   US and French authorities have authorised the use of chloroquine and hydroxychloroquine, but the EU regulator and WHO say the science doesn’t support the decision. Susan Jaffe reports. 
With no “adequate, approved and available” alternative, the US Food and Drug Administration (FDA) is allowing the use of the antimalarial drugs hydroxychloroquine and chloroquine to treat coronavirus disease 2019 (COVID-19).

The FDA’s emergency use authorisation (EUA) issued last week gives physicians the option to prescribe the drugs, which President Donald Trump has recommended. However, both drugs are unproven and untested for COVID-19, and have rare but potentially deadly side-effects.  The decision bypassed the usual drug approval process including doubleblind, placebo-controlled clinical trials, stoking a worldwide debate about whether the drugs are appropriate for treating the disease.

“I think it was resorted to more out of a sense of desperation”, said Joseph Masci, an infectious disease specialist and director of global health at Elmhurst Hospital in Queens, a borough of New York City, which is at the centre of the epidemic in the USA. “It is just an indication of how sudden and massive this outbreak has been.” [Continued here.]  

Congressional showdown threatens NIH funding boost

lancet cover 2Volume 386, Issue 9996,  29 August 2015

WORLD REPORT    Bills providing extra funding for the National Institutes of Health while cutting other programmes could a face presidential veto.  Susan JaffeThe Lancet’s Washington correspondent,  reports.

After years of mostly stagnant funding for the US National Institutes of Health (NIH), two powerful congressional committees that control government spending have approved separate budget bills containing record increases for the agency.
But last month, President Barack Obama’s Office of Management and Budget director Shaun Donovan wrote to the chairman of the Senate Committee on Appropriations warning that he expects the president to veto its bill. Among other reasons, Donovan said it “drastically” cuts money for public health programmes including Medicare for the elderly and Medicaid, serving low-income Americans. And it would deny funds for operating the health insurance exchanges essential to the president’s signature health reform law, the Affordable Care Act. [Continued in full text or PDF ]